Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Carlton D. Dampier, MD
Researcher Professor
Department of Pediatrics
Emory University School of Medicine
2015 Uppergate Dr NE
Atlanta, Georgia, United States
Dr. Carlton Dampier is a pediatric hematologist-oncologist in Atlanta, Georgia and is affiliated with multiple hospitals in the area, including Children’s Healthcare of Atlanta and Grady Memorial Hospital. He received his medical degree from University of Chicago Pritzker School of Medicine and has been in practice for more than 20 years. His broad research interest is the assessment of patient-reported outcomes and subsequent symptom management in children and adolescents, particularly those with pain from sickle cell disease. He has led or participated in a number of studies validating specific assessment tools, as well as longitudinal observation studies examining symptom frequency by self-report or parent-proxy reporting. He has led or participated in a number of clinical trials of analgesics or investigational drugs for the treatment of vaso-occlusive sickle cell pain. As a research administrator, he has a broad interest in process improvement and quality management of clinical trials, as well as research ethics and scientific integrity in the conduct of clinical trials.
Representative Publications:
Red blood cell alloimmunization in sickle cell disease: prevalence in 2010
Inpatient management of sickle cell pain: a ‘snapshot’ of current practice
Definitions of the phenotypic manifestations of sickle cell disease
Related Content
-
Megan Davis, MDDr. Megan Davis received her medical deg...
-
Edith Aimiuwu, RGNEdith Aimiuwu was trained as a registere...
-
Impact of emergency department care on outcomes of acute pain events in children with sickle cell diseaseThe impact of emergency department (ED) ...
-
Sickle cell pain in the emergency departmentSickle cell disease is characterized by ...
-
High ED Utilization and Perceptions of Opioid Addictionhttps://www.youtube.com/watch?v=9xJ4VwtB...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
-
4 Transition Stages of Sickle Cell Disease and Tips for Each Stagehttps://www.onescdvoice.com/wp-content/u...
+myBinder